Form 4: Artivion SVP Sells Shares After Option Exercise
Insider Transaction Report
Artivion's SVP of Clinical & MD Affair, Marshall S. Stanton, sold common stock on November 20, 2025, following the exercise of stock options.
Summary
- Marshall S. Stanton, SVP, Clinical & MD Affair at Artivion, Inc. (AORT), reported multiple transactions on November 20, 2025.
- Stanton exercised 2,033 stock options at an exercise price of $18.44, acquiring 2,033 shares of common stock.
- Concurrently, Stanton sold 2,033 shares of common stock at a weighted average price of $44.315, with prices ranging from $44.26 to $44.44.
- Stanton also exercised 1,355 stock options at an exercise price of $11.03, acquiring 1,355 shares of common stock.
- Following this exercise, Stanton sold 1,355 shares of common stock at a weighted average price of $44.278, with prices ranging from $44.26 to $44.35.
- An additional 11,888 shares of common stock were sold by Stanton at a weighted average price of $44.14, with prices ranging from $43.92 to $44.49.
- After these reported transactions, Stanton directly beneficially owns 44,753 shares of Artivion common stock.
- Remaining derivative securities include 20,301 stock options with an exercise price of $18.44 and 27,075 stock options with an exercise price of $11.03.
Sentiment
Score: 5
Explanation: The filing is a factual report of insider transactions and does not contain information to indicate a positive or negative sentiment regarding the company's operational performance or future prospects.
Positives
- The reporting person realized significant gains by exercising stock options at lower prices ($18.44 and $11.03) and selling the acquired shares at higher market prices (around $44).
Negatives
- An insider, Marshall S. Stanton, sold a total of 15,276 shares of common stock (11,888 + 2,033 + 1,355) in the open market, which some investors might interpret as a signal, though often it is for personal financial planning or diversification.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the sale of shares by a Senior Vice President as a routine personal financial decision, especially when tied to option exercises, or potentially as a signal regarding the executive's confidence in the company's near-term stock performance.
Key Dates
| Date | Description |
|---|---|
| 02/23/2023 | First exercisable date for 2,033 stock options granted, vesting 33 1/3% per year from grant date. |
| 11/08/2023 | First exercisable date for 1,355 stock options granted, vesting 33 1/3% per year from grant date. |
| 11/20/2025 | Date of reported transactions, including stock option exercises and common stock sales. |
| 11/24/2025 | Signature date of the reporting person for the Form 4 filing. |
| 02/23/2029 | Expiration date for 2,033 stock options with an exercise price of $18.44. |
| 11/08/2029 | Expiration date for 1,355 stock options with an exercise price of $11.03. |
Keywords
ARTIVION, AORT, insider trading, Form 4, stock options, share sale, executive compensation, Marshall S. Stanton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.